FINWIRES · TerminalLIVE
FINWIRES

JPMorgan Downgrades Mereo BioPharma to Underweight From Neutral

By

Mereo BioPharma Group (MREO) has an average rating of overweight and mean price target of $2, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles